InsiderSignal.AI

InsiderSignal.ai

PTGX - Protagonist Therapeutics, Inc

Insider Sale by Ali Asif (CFO)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

2 days ago, Ali Asif, serving as CFO at Protagonist Therapeutics, Inc (PTGX), sold 1,750 shares at $105.47 per share, for a total transaction value of $184,573.00. Following this transaction, Ali Asif now holds 59,003 shares of PTGX.

This sale represents a 3.00% decrease in Ali Asif's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, April 20, 2026 and publicly disclosed via SEC Form 4 filing on Tuesday, April 21, 2026, 1 day after the trade was made.

Protagonist Therapeutics, Inc operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Ali Asif

Ali Asif

CFO

Ali Asif is the Chief Financial Officer (CFO) of Protagonist Therapeutics, Inc. (NASDAQ: PTGX), a biopharmaceutical company focused on peptide-based therapeutics.[[1]](https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-appointment-of-asif-ali-as-executive-vice-president-and-chief-financial-officer-301511556.html)[[3]](http://www.protagonist-inc.com/executive-team) He joined the company in April 2022 as Executive Vice President and CFO, overseeing financial planning and analysis, taxation, accounting, financial reporting, finance operations, investor relations, and strategic financings.[[1]](https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-appointment-of-asif-ali-as-executive-vice-president-and-chief-financial-officer-301511556.html)[[3]](http://www.protagonist-inc.com/executive-team) Prior to Protagonist, Asif served as Chief Accounting Officer at Theravance Biopharma, where he managed equity and asset-backed financings, strategic collaborations, finance operations, and international tax planning, including raising $130 million in equity financing in February 2020 and $115 million in June 2021.[[1]](https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-appointment-of-asif-ali-as-executive-vice-president-and-chief-financial-officer-301511556.html)[[3]](http://www.protagonist-inc.com/executive-team) Previously, as Vice President and Controller at Depomed, Inc., he supported five product launches, four product acquisitions, and a significant financing from the sale of future royalties.[[1]](https://www.prnewswire.com/news-releases/protagonist-therapeutics-announces-appointment-of-asif-ali-as-executive-vice-president-and-chief-financial-officer-301511556.html) Asif recently sold 46,203 shares of PTGX stock on January 27, 2026, for approximately $3.8 million while exercising options for 28,000 shares.[[2]](https://www.investing.com/news/insider-trading-news/ali-asif-cfo-of-protagonist-sells-38m-in-ptgx-stock-93CH-4469129)[[6]](https://fr.tradingview.com/news/tradingview:37ec08a656b75:0-protagonist-therapeutics-executives-sell-shares/)[[8]](https://www.ainvest.com/news/protagonist-therapeutics-ceo-buys-sells-shares-price-surge-2601/)

View full insider profile →

Trade Price

$105.47

Quantity

1,750

Total Value

$184,573.00

Shares Owned

59,003

Trade Date

Monday, April 20, 2026

2 days ago

SEC Filing Date

Tuesday, April 21, 2026

Filed 1 day after trade

HEALTHCAREBIOTECHNOLOGY

About Protagonist Therapeutics, Inc

Company Overview

No company information available
View news mentioning PTGX

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/5829249

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

Create Free AccountLearn More

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime